Vaxcyte reported positive top-line data from the OPUS-1 Phase 3 trial of its 31-valent pneumococcal conjugate vaccine candidate, VAX-31. The result demonstrates its ability to provide broader coverage through a focused carrier-sparing platform.
Vaxcyte reported positive top-line data from the OPUS-1 Phase 3 trial of its 31-valent pneumococcal conjugate vaccine candidate, VAX-31. The result demonstrates its ability to provide broader coverage through a focused carrier-sparing platform.